PMID: 9167751Jun 1, 1997Paper

Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP)

American Journal of Clinical Oncology
A BallestreroF Patrone

Abstract

High-dose chemotherapy often requires hematopoietic progenitor cell reinfusion, but drugs with extramedullary dose-limiting toxicity may be administered in the high-dose range by simple growth factor support. In this study, we evaluated the feasibility and toxicity of a three-drug high-dose regimen supported by recombinant human granulocyte colony-stimulating factor (rhG-CSF). Ten patients with histologically proven malignancy were enrolled. Eight had breast cancer, one non-Hodgkin's lymphoma, and one a mediastinal tumor of unknown origin. The regimen included cyclophosphamide (C) 5 g/m2, etoposide (E) 1.5 g/m2, and cisplatin (P) 150 mg/m2 (CEP), administered in a 3-day schedule followed by rhG-CSF, 300 micrograms once a day, beginning from day +5 (36 h after the end of chemotherapy). The cycle was repeated as clinically needed up to three times. After the first course, hematologic recovery was rapid and complete without documented infections, and no relevant extramyeloid toxicities were observed. Eight of 10 patients received a second course with comparably low toxicity, and three of them received a third course. We concluded that CEP therapy can be administered safely and even repeatedly, by simple growth factor support, in g...Continue Reading

References

Sep 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A NeidhartF B Oldham
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J P DrozM Hayat
Oct 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A NeidhartJ J Rinehart
Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F R DunphyR O Wallerstein
Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J NeidhartM Downing
May 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D H JohnsonF A Greco
Jun 1, 1988·Investigational New Drugs·W M Holleran, M W DeGregorio
Apr 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F PatroneM Sessarego
Jul 1, 1994·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·T BeckA Wree

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.